QUANTITATIVE ANALYSIS OF HIV-1 PROVIRAL DNA IN SAMPLES FROM PATIENTS WITH AIDS

一种快速、简便的前病毒DNA含量测定方法 来自人类感染性疾病患者的外周血单个核细胞（PBM） 免疫缺陷病毒I型（HIV-1）感染是通过使用 聚合酶链反应（PCR）技术。我们发现大多数人 在未分级PBM中可检测到的HIV前病毒DNA拷贝数中， 细胞，而B细胞/单核细胞含有较少量的HIV DNA（93.9+- T细胞为3.5%，而B细胞/单核细胞为6.1 ± 3.5%：p<0.05）。当我们 比较了13例AIDS患者PBM中HIV前病毒DNA的含量 或ARC之前和期间的抗逆转录病毒治疗与2 '，3'双脱氧肌苷 (ddI)在一项I期临床研究中， 在12例可评价患者中的9例中观察到显著降低 用药8 ~ 14周（p<0.02）。下降出现得更多 在接受相对高剂量药物的患者中明显。 这些数据表明，通过PCR定量PBM中的HIV病毒DNA是可行的。 可行，理论上可能有助于全面监测 接受实验性治疗的患者。然而，更大的研究将是 确定本试验的灵敏度和特异性所需， 进一步的纵向研究是必不可少的。

A rapid and simple method for determining the proviral DNA content in peripheral blood mononuclear cells (PBM) from patients with human immunodeficiency virus type I (HIV-1) infection was established by using the polymerase chain reaction (PCR) technique. We found that the majority of HIV proviral DNA copies detectable in unfractionated PBM resided in T cells, while B cells/monocytes contained lesser amounts of HIV DNA (93.9+- 3.5% for T cells versus 6.1+-3.5% for B cells/monocytes: p<0.05). When we compared the amount of HIV proviral DNA in PBM from 13 patients with AIDS or ARC before and during antiretroviral therapy with 2',3'dideoxyinosine (ddI) which was given as an escalating dose in a phase I clinical study, a significant decrease was observed in 9 out of 12 evaluable patients receiving the drug for 8 to 14 weeks (p<0.02). The decrease appeared more pronounced in patients receiving relatively high doses of the drug. These data suggest that the quantitation of HIV viral DNA in PBM by PCR is feasible and may theoretically contribute to an overall monitoring of patients receiving experimental therapy. However, larger studies will be required to determine the sensitivity and specificity of this assay and further longitudinal studies will be essential.